HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2025
0mins
Source: Globenewswire
Skin Cancer Statistics and Awareness: Nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma advance to difficult-to-treat stages annually, with the incidence tripling over three decades due to aging and sun damage; May is Skin Cancer Awareness Month highlighting this growing burden.
Innovative Treatment Success: A new investigational drug, designed to activate in the tumor microenvironment, has shown promising results in a clinical trial at HonorHealth Research Institute, where a patient experienced no detectable cancer after treatment, offering hope for those with limited options.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
